Introduction
bioregulator of eicosanoid and cytokine production. 1 Since damage of the endothelial cell can Several experimental models have been be a prime event leading to mucosal injury, this described which resemble human inflammatory could reflect a diminished release of the endobowel disease (IBD), including ulcerative colitis thelial derived mediators prostacyclin (PGI2) and (UC) and Crohn's disease (CD). These animal nitric oxide (NO). On the contrary, we have models have been used to examine the produc-found high amounts of the 15-1ipoxygenase tion of inflammatory mediators by intestinal product 15-hydroxy-eicosatetraenoic acid (15- mucosa and to determine the effects of various HETE) in human colonic mucosa. 1 This subdrugs on inflammation and on individual media-stance is synthesized both by endothelial cells tots. 2'3 The customary drugs used in IBD--cort-and macrophages. The minor anti-inflammatory icosteroids and 5-aminosalicylates--are thought effects of 15-H(P)ETE could be ascribed to to act by interfering with eicosanoid produc-inhibition of the pro-inflammatory mediator tion. 4 In IBD, the synthesis of leukotriene B4 LTB4. 2 It has been suggested that cytokines (LTB4) in colonic mucosa has been shown to such as turnout necrosis factor (TNFa) and be enhanced compared with its production in interleukin-I (IL-1) are primary triggers of the normal tissue. 5 However, specific 5-1ipoxygenase initial inflammation, 3 whereas platelet-activating inhibitors such as Zileuton have not been factor (PAF)is considered to be involved as a shown to have marked beneficial effects on secondary trigger, resulting in a chronic phase inflammation in man, although LTB4 levels in of the inflammation. 4 This hypothesis implies dialysates were decreased. 6 Prostaglandin E2 that the choice of drug therapy for IBD might (PGE2) is also increased in dialysates 7 and depend on the stage of the disease. In the mucosal tissue s of patients with UC and CD.
search for a suitable model for UC resembling However, the anti-inflammatory effects of this acute, and chronic inflammation of colonic substance are well documented, 9 shown in Fig. 1 . In the control group, which contained mice that had not been treated with DSS, no inflammatory activity was observed ( Fig.  2(a) ).
The group treated for 2 days with 10% DSS solution and then killed at the second day of the treatment schedule, showed a significant increase in the inflammation score. The maximum inflammation score was seen after 4 days treatment with 10% DSS (Fig. 2(b) ). The inflammation score of the fourth and fifth group, in which the DSS concentration in the drinking water was reduced to 2% (w/v) on the fifth day of the treatment schedule, showed a significant decrease of the inflammation score compared with groups which had been treated with 10% DSS for 2 or 4 days. Compared with the control group, however, inflammatory activity was still present (Fig. 2(c) ). The production of NO, 6kPGFla and PGE2 in 100 mg tissue decreased significantly during the initial phase (d2-d4) of the inflammation (Fig.   3 ). The production of LTB 4 and LTC4 was extremely low in comparison with PGs (1-4 vs. 500-3500 pg/mg wet tissue, data not shown) and did not change significantly. The production of the cytokines TNFa and IL-1[3 was only increased in the first two days (initial phase) of DSS treatment. The production of PAF was unchanged during the initial phase, whereas a marked increase of PAF production was observed (d8) after the concentration of DSS was reduced (Fig.  4) .
Discussion
Dextran sodium sulfate induced a diffuse inflammatory response in the colonic mucosae of 7 and the pro-inflammatory IL-I. 24 These non-selective inhibitory actions could explain why both the initial and the chronic phase of inflammation are successfully treated by this group of compounds. Sulfasalazine derived compounds such as 5-amino-salicylates (5-ASA) non-selectively inhibit eicosanoid formation in dextran sulfate induced colitis in mice, 25 whereas we previously found that 5-ASA increases rather than inhibits PAF synthesis. 16 This effect of 5-ASA on PAF might explain the fact that exacerbations during chronic colitis are well treated by 5-ASA compounds, but total remission is not achieved in many cases.
Further investigations with specific synthesis inhibitors and soluble receptor antagonists are needed to gain more insight in the importance of the sequential release of pro-and anti-inflammatory mediators during acute and chronic colitis.
